Celgene Corp. (NASDAQ:CELG) markets four billion-dollar blockbuster medicines, but only two were behind its stellar sales and profit performance in the second quarter. Sales of Revlimid grew 21% to $2.4 billion, and Pomalyst sales increased 30% to $507 million. Can these multiple myeloma drugs continue to deliver growth for Celgene's investors?
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,